American Society of Hirudotherapy

Impact of postoperative complications on patient-reported outcomes in deep inferior epigastric perforator flap breast reconstruction.

Research article published in Breast cancer (Tokyo, Japan) (2025)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportClinical TrialsGuo et al. · Breast cancer (Tokyo, Japan), 2025

Abstract

OBJECTIVE: This study aims to investigate the factors that influence the occurrence of complications following deep inferior epigastric perforator (DIEP) flap breast reconstruction, and to determine whether these complications have an impact on the patient's quality of life in China. METHODS: We collected clinical data from patients who underwent DIEP flap breast reconstruction at the Department of Breast, Affiliated Cancer Hospital of Zhengzhou University between December 2019 and December 2023. We analyzed the incidence of postoperative complications and their relationship with patient clinical data and surgical parameters. We also used the BREAST-Q 2.0 Chinese version scale to assess the impact of postoperative complications on patient-reported outcomes. RESULTS: A total of 109 patients underwent DIEP flap breast reconstruction, including 91 stage I reconstructions and 18 stage II reconstructions. Postoperative complications occurred in 26 cases (23.9%), including flap complications in 13 cases (11.9%) and abdominal donor-site complications in 13 cases (11.9%). Univariate and multivariate analyses showed that the overall incidence of complications was associated with high BMI and early surgery (P < 0.05). Flap complications were associated with high BMI, early surgery, and the use of internal mammary vascular branches as recipient vessels (P < 0.05). Abdominal complications were associated with previous abdominal surgery scars (P < 0.05). Approximately 20% of patients did not complete the BREAST-Q questionnaires (including the two patients who experienced total flap loss). BREAST-Q scores showed no significant differences between the surgical complication group and the no-complication group in terms of breast satisfaction, mental health, physical health-chest, physical health-abdomen, satisfaction with abdomen, sexual health, etc. (P > 0.05). CONCLUSION: Patients who underwent DIEP flap breast reconstruction revealed that high BMI, neoadjuvant therapy, and abdominal incision scars may influence postoperative complications. The limited follow-up data indicated that postoperative complications did not impact patient-reported outcomes.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansFemaleMammaplastyPerforator FlapPostoperative ComplicationsMiddle AgedPatient Reported Outcome MeasuresBreast NeoplasmsQuality of LifeAdultChinaEpigastric Arteries

Summary

This study aims to investigate the factors that influence the occurrence of complications following deep inferior epigastric perforator (DIEP) flap breast reconstruction, and to determine whether these complications have an impact on the patient's quality of life in China. We collected clinical...

Why This Matters for Hirudotherapy

This study analyzed 109 DIEP flap breast reconstructions at a Chinese cancer hospital, reporting a 23.9% overall complication rate (flap and donor-site complications each 11.9%) associated with high BMI, early surgical experience, and prior abdominal scars; patient-reported BREAST-Q outcomes showed no significant differences between complication and no-complication groups. While flap complications represent scenarios where leech therapy might theoretically be employed for venous congestion, this study does not mention or evaluate leech use. The work offers indirect background on complication patterns in flap reconstruction but provides no direct evidence relevant to hirudotherapy practice.

Citation

Impact of postoperative complications on patient-reported outcomes in deep inferior epigastric perforator flap breast reconstruction.

Guo et al. · Breast cancer (Tokyo, Japan), 2025

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.